Genomics

A Cambridge startup is building a 'Common Crawl for the living world,' framing biological data as a strategic weapon in the US-China tech rivalry.

A €2M EU grant is funding a Singapore-led initiative to turn wastewater into a high-tech early warning system for disease outbreaks across Asia.

As Vivos Therapeutics pitches its revolutionary sleep apnea solution to investors, it's not just selling a device; it's fighting for its financial life.

A deadly, vaccine-less Ebola strain is spreading in Central Africa. As governments scramble, the CDC Foundation deploys its most potent weapon: agile funding.

New research from Baycrest unmasks paratonia, an involuntary condition often mistaken as defiance, signaling a seismic shift in dementia care and treatment.

As Capricor presents its late-stage DMD drug and novel exosome platform, can it convince investors it has the key to both patient impact and market success?

An aging world and failing antibiotics are driving a surge in pneumonia. Now, a new generation of therapies is being built to fight back. Here's how.

As GLP-1 drugs dominate, a UK biotech reveals a new drug that targets mitochondria, promising superior fat loss while preserving precious muscle mass.

With expanded coverage for 52 million Americans, Tonix Pharmaceuticals' TONMYA® is not just a drug launch; it's a market disruption for chronic pain.

Phenomenex, a Danaher company, launches its Luna Omega HILIC columns, aiming to simplify complex analysis in pharma, food safety, and diagnostics.

With its new SmartBioSurface slides, Italian firm Tethis aims to solve a major lab challenge. The key? A nanotech surface that could reshape disease research.

Zealand Pharma's petrelintide shows double-digit weight loss with remarkably few side effects, positioning it to challenge GLP-1 giants in the $100B market.

DBV Technologies heads to a key investor conference with its VIASKIN patch for peanut allergies. Can its science and strategy convince Wall Street?

Market research shows doctors are eager to prescribe Moleculin's new AML drug, Annamycin. It offers hope where there is none, but can the company survive to deliver it?

A new class of doctor is bridging the gap between lab and patient. Meet the physician-scientists tackling deadly diseases with revolutionary new approaches.

A pharma revolution is brewing for Generalized Anxiety Disorder. As prevalence soars, novel therapies targeting new neural pathways promise to upend the market.

A new diagnostic tool, Delve Detect, is using metagenomic sequencing to unmask elusive pathogens in the brain, offering hope where conventional tests fail.

A Florida biotech is using a novel gene therapy to correct aging-related errors. But the real story is its funding: a decentralized, crypto-style model.

The market for T-cell malignancy treatments is set to surpass $1.8B, fueled by a pipeline of innovative drugs aiming to meet vast unmet patient needs.

Perspective Therapeutics is testing a potent alpha-particle therapy for meningioma, the most common brain tumor, offering a new option where surgery fails.